Recombinant Dog CTSK Protein, His/GST-tagged

• Cat.No.: CTSK-328D
• Product Overview: Recombinant Dog CTSK(Thr71~Cys319) fused with His/GST tag at N-terminal was expressed in E. coli.

Specification

• Description: CTSK played an important role in many functions.
• Source: E. coli
• Species: Dog
• Tag: His&GST
• Form: PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
• Molecular Mass: 59.5kDa
• Identity: Reconstitute in PBS or others
• Protein length: Thr71~Cys319
• Endotoxin: <1.0EU per 1µg (determined by the LAL method)
• Purity: > 95%
• Applications: Positive Control; Immunogen; SDS-PAGE; WB.
  If bio-activity of the protein is needed, please check active protein
• Stability: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37 centigrade for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
• Storage: Avoid repeated freeze/thaw cycles. Store at 2-8 centigrade for one month. Aliquot and store at -80 centigrade for 12 months.
• Reconstitution: Reconstitute in PBS or others

Gene Information

• Gene Name: CTSK cathepsin K [ Canis lupus familiaris ]
• Official Symbol: CTSK
• Synonyms: CTSK; cathepsin K; cathepsin K (pycnodysostosis)
• Gene ID: 608843
• mRNA Refseq: NM_001033996
• Protein Refseq: NP_001029168
• UniProt ID: Q3ZKN1

Reviews

09/13/2019

This guidance can help researchers design and execute their experiments more effectively, ensuring reliable and accurate results.

01/27/2019

They have a deep understanding of the CTSK protein and can provide valuable insights into its characteristics, properties, and optimal experimental conditions.

12/14/2016

the manufacturer offers outstanding technical support, serving as a valuable resource to resolve any issues that may arise during my research.

Q&As

Can CTSK be a target for the development of novel therapeutics for periodontal diseases?

Yes, CTSK inhibitors are being investigated for their potential in preventing bone loss associated with periodontal diseases.

How does CTSK contribute to the progression of atherosclerosis, and can it be a therapeutic target for cardiovascular diseases?

CTSK has been linked to vascular calcification in atherosclerosis, and inhibiting its activity may have potential as a therapeutic strategy for cardiovascular diseases.

How might CTSK inhibitors impact the treatment landscape for bone metastasis in cancer patients?

CTSK inhibitors could potentially be used to limit bone destruction in cancer patients with bone metastasis, improving their quality of life.

Are there any other medical conditions where CTSK inhibitors could be beneficial?

CTSK inhibitors are being explored for potential therapeutic applications in conditions like rheumatoid arthritis and certain cancers due to their involvement in tissue remodeling.

Are there diagnostic applications for CTSK in identifying bone-related disorders?

While CTSK is not currently used as a diagnostic marker, its levels and activity could potentially be explored for diagnostic purposes in the future.